Year All2026202520242023202220212020201920182017 May 8, 2026 ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update Read more May 7, 2026 ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression Read more April 30, 2026 ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026 Read more April 17, 2026 ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules Read more April 13, 2026 ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer Read more February 27, 2026 ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update Read more February 19, 2026 ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026 Read more February 19, 2026 ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 Read more January 30, 2026 ALX Oncology Announces Pricing of Underwritten Offering Read more January 30, 2026 New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer Read more